William Blair LLC discloses 8.6% stake in Twist Bioscience (NASDAQ: TWST)
Filing Impact
Filing Sentiment
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary
Twist Bioscience Corp ownership update: William Blair Investment Management, LLC filed Amendment No. 2 to a Schedule 13G/A reporting beneficial ownership of 5,269,718 shares of Common Stock, representing 8.6% of the class. The filer reports sole voting power over 4,836,983 shares and sole dispositive power over 5,269,718 shares. The filing is signed by the Chief Compliance Officer on 05/07/2026.
Positive
- None.
Negative
- None.
Key Figures
Beneficial ownership: 5,269,718 shares
Percent of class: 8.6%
Sole voting power: 4,836,983 shares
+2 more
5 metrics
Beneficial ownership
5,269,718 shares
reported in Schedule 13G/A Amendment No. 2
Percent of class
8.6%
percent of common stock beneficially owned
Sole voting power
4,836,983 shares
shares over which the filer has sole vote
Sole dispositive power
5,269,718 shares
shares over which the filer has sole disposition
Filing signature date
05/07/2026
date the amendment was signed
Key Terms
Schedule 13G/A, beneficial ownership, sole dispositive power, sole voting power
4 terms
Schedule 13G/A regulatory
"Amendment No. 2 to a Schedule 13G/A reporting beneficial ownership"
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.
beneficial ownership financial
"Amount beneficially owned: 5,269,718 and Percent of class: 8.6%"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
sole dispositive power regulatory
"Sole power to dispose or to direct the disposition of: 5,269,718"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
sole voting power regulatory
"Sole power to vote or to direct the vote: 4,836,983"
Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.
FAQ
What stake did William Blair report in Twist Bioscience (TWST)?
William Blair reported beneficial ownership of 5,269,718 shares, equal to 8.6% of Twist Bioscience's common stock. The filing lists sole voting power over 4,836,983 shares and sole dispositive power over 5,269,718 shares.
What type of filing was submitted for TWST?
An Amendment No. 2 to a Schedule 13G/A was filed, updating beneficial ownership information for Twist Bioscience. The filing amends prior Schedule 13G disclosures and reports current holdings and voting/dispositive powers.
Who signed the Schedule 13G/A amendment for TWST?
The amendment was signed by Telmo Martins, Chief Compliance Officer of William Blair Investment Management, LLC, with the signature dated 05/07/2026. The filer’s listed jurisdiction is Delaware.
Where is Twist Bioscience's principal executive office listed in the filing?
The filing lists the issuer's principal executive office at 681 Gateway Blvd., South San Francisco, California 94080. This address is provided under the item identifying the issuer.